| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 44,320 | 25,297 | ||
| Restricted cash and cash equivalents | 100 | 100 | ||
| Prepaid expenses and other current assets | 4,631 | 4,050 | ||
| Total current assets | 49,051 | 29,447 | ||
| Operating lease right-of-use assets | 556 | 683 | ||
| Goodwill | 1,914 | 1,914 | ||
| Deposits and other assets | 34 | 261 | ||
| Total assets | 51,555 | 32,305 | ||
| Accounts payable | 2,305 | 3,336 | ||
| Accrued expenses and other current liabilities | 3,021 | 2,083 | ||
| Operating lease liabilities | 599 | 580 | ||
| Total current liabilities | 5,925 | 5,999 | ||
| Operating lease liabilities, non-current | 0 | 157 | ||
| Total liabilities | 5,925 | 6,156 | ||
| Common stock, 0.0001par value 350,000,000shares authorized, 125,078,525 and 73,977,459shares issued and outstanding at september30, 2025 and december31, 2024, respectively | 12 | 10 | ||
| Additional paid-in capital | 312,948 | 286,678 | ||
| Accumulated deficit | -267,330 | -260,539 | ||
| Total stockholders equity | 45,630 | 26,149 | ||
| Total liabilities and stockholders equity | 51,555 | 32,305 | ||
SELLAS Life Sciences Group, Inc. (SLS)
SELLAS Life Sciences Group, Inc. (SLS)